Peter G. Ballard

5.2k citations

47 papers · 4.4k · 3 hit papers · h-index 22

Impact in

Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations
Oncology top 2%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies

Papers in

Oncology 17
- HER2/EGFR in Cancer Research 13
Pulmonary and Respiratory Medicine 14
- Lung Cancer Treatments and Mutations 13

Co-authors: Mireille Cantarini (4 shared papers)Kathryn Pickup (2 shared papers)Darren A.E. Cross (5 shared papers)James W.T. Yates (3 shared papers)James Chih‐Hsin Yang (2 shared papers)Pasi Antero Janne (3 shared papers)Matthew R. Box (1 shared paper)Zhenfan Yang (1 shared paper)
Journals: Bioorganic & Medicinal Chemistry Letters (10 papers)Journal of Pharmaceutical and Biomedical Analysis (5 papers)Journal of Medicinal Chemistry (4 papers)Pharmaceutical Research (3 papers)Annals of Oncology (2 papers)
Partner nations: United Kingdom France United States

In The Last Decade

Peter G. Ballard

47 papers receiving 4.3k citations

Peter G. Ballard's Hit Papers

align trajectories log scale

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity 2016 · 602 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2016 Clinical Cancer Research
2014 Journal of Medicinal Chemistry
2014 Cancer Discovery

Peers

Countries citing papers authored by Peter G. Ballard

Since Specialization

Citations

This map shows the geographic impact of Peter G. Ballard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. Ballard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. Ballard more than expected).

Fields of papers citing papers by Peter G. Ballard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter G. Ballard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. Ballard. The network helps show where Peter G. Ballard may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter G. Ballard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter G. Ballard Line = papers co-authored together Peter G. Ballard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Cancer Discovery ·Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay Hit paper breakdown →	2014	1867
2	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Clinical Cancer Research ·Peter G. Ballard, James W.T. Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela C. Jordan Hit paper breakdown →	2016	602
3	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor Journal of Medicinal Chemistry ·M. Raymond V. Finlay, Mark J. Anderton, Susan E. Ashton, Peter G. Ballard, Paul A. Bethel, Matthew R. Box, Robert Hart Bradbury, Simon J. Brown Hit paper breakdown →	2014	520
4	Discovery of 4-Amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases Journal of Medicinal Chemistry ·Matt Addie, Peter G. Ballard, David Buttar, Claire Crafter, Gordon S. Currie, Barry R. Davies, Judit Debreczeni, Hannah Dry	2013	199
5	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1 -Mutant Breast Tumors in Preclinical Models Cancer Research ·Hazel M. Weir, Robert Hart Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena J. Callis, Jon Curwen, Camila de Almeida	2016	161
6	Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist Journal of Medicinal Chemistry ·Chris De Savi, Robert Hart Bradbury, Alfred A. Rabow, Richard A. Norman, Camila de Almeida, David M. Andrews, Peter G. Ballard, David Buttar	2015	148
7	Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor Drug Metabolism and Disposition ·Paul Alfred Dickinson, Mireille Cantarini, J. Collier, Paul Frewer, Scott W. Martin, Kathryn Pickup, Peter G. Ballard	2016	114
8	Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Richard Ducray, Peter G. Ballard, Bernard C. Barlaam, Mark D. Hickinson, Jason G. Kettle, Donald Ogilvie, Catherine B. Trigwell	2007	71
9	Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label CPT Pharmacometrics & Systems Pharmacology ·Venkatesh Pilla Reddy, Michael Luke Walker, Pradeep Kumar Sharma, Peter G. Ballard, Karthick Vishwanathan	2018	54
10	Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells Atherosclerosis ·Linda K. Buckett, Peter G. Ballard, Robert G. Davidson, C. R. Dunkley, Lenox D. Martin, John M. Stafford, Fergus McTaggart	2000	53
11	Determination of microsome and hepatocyte scaling factors forin vitro/in vivoextrapolation in the rat and dog Xenobiotica ·Roy E. Smith, Rhys D. O. Jones, Peter G. Ballard, Heledd Jarosz-Griffiths	2008	51
12	The right compound in the right assay at the right time: an integrated discovery DMPK strategy Drug Metabolism Reviews ·Peter G. Ballard, Patrick J. Brassil, Khanh Hong-Thien Bui, Hugues Dolgos, Carl Johan Petersson, Anders Tunek, Peter J. H. Webborn	2012	49
13	Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer Bioorganic & Medicinal Chemistry Letters ·Robert Hart Bradbury, Neil J. Hales, Alfred A. Rabow, Graeme E. Walker, David G. Acton, David M. Andrews, Peter G. Ballard, Nigel A.N. Brooks	2011	38
14	Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104 Molecular Cancer Therapeutics ·James W.T. Yates, Susan E. Ashton, Darren A.E. Cross, Martine J. Mellor, Steve J. Powell, Peter G. Ballard	2016	37
15	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket Bioorganic & Medicinal Chemistry Letters ·Peter G. Ballard, Robert Hart Bradbury, Craig Steven Harris, Laurent François Hennequin, Mark D. Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa C. M. Klinowska	2005	34
16	5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase Bioorganic & Medicinal Chemistry Letters ·Peter G. Ballard, Robert Hart Bradbury, Laurent François Hennequin, D. Mark Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa C. M. Klinowska, Rémy Morgentin	2005	33
17	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors ACS Medicinal Chemistry Letters ·Bernard C. Barlaam, Judith Anderton, Peter G. Ballard, Robert Hart Bradbury, Laurent François Hennequin, D. Mark Hickinson, Jason G. Kettle, George G. Kirk	2013	33
18	Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo Bioorganic & Medicinal Chemistry Letters ·Richard W. A. Luke, Peter G. Ballard, David Buttar, Leonie Campbell, Jon Curwen, Steve C. Emery, Alison M. Griffen, Lorraine A. Hassall	2009	31
19	Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics Bioorganic & Medicinal Chemistry Letters ·Peter G. Ballard, Robert Hart Bradbury, Craig Steven Harris, Laurent François Hennequin, Mark D. Hickinson, Jason G. Kettle, Jane Kendrew, Teresa C. M. Klinowska	2006	30
20	Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis Journal of Medicinal Chemistry ·Jason G. Kettle, Peter G. Ballard, Catherine Bardelle, Mark J. Cockerill, Nicola Colclough, Susan E. Critchlow, Judit Debreczeni, Gary Fairley	2015	28

About Peter G. Ballard

Peter G. Ballard is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry, Pharmacology and Radiology, Nuclear Medicine and Imaging, having authored 47 papers that have together received 4.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (13 papers), Quinazolinone synthesis and applications (10 papers), Analytical Chemistry and Chromatography (4 papers), Estrogen and related hormone effects (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Cancer therapeutics and mechanisms (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.4k citations), Oncology (1.8k citations), Organic Chemistry (751 citations), Cancer Research (349 citations) and Molecular Biology (1.7k citations). Peter G. Ballard has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Mireille Cantarini, Kathryn Pickup, Darren A.E. Cross, James W.T. Yates, James Chih‐Hsin Yang, Pasi Antero Janne, Matthew R. Box, Zhenfan Yang, Dong‐Wan Kim and Jonas Malmquist. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Pharmaceutical and Biomedical Analysis, Journal of Medicinal Chemistry, Pharmaceutical Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter G. Ballard

Impact in

Papers in i

In The Last Decade

Peter G. Ballard

Peter G. Ballard's Hit Papers

Peers

Countries citing papers authored by Peter G. Ballard

Fields of papers citing papers by Peter G. Ballard

All Works

About Peter G. Ballard

Explore authors with similar magnitude of impact

Papers in